Managing Director, US
Managing Director, US Life Sciences
Of Counsel
B.Sc. (Chemistry), JD, LL.M.
Patent Attorney (US)
Patent Agent (Can)
Trademark Attorney/Agent (US/Can)
+1-617-861-3924
Alan is a highly regarded U.S. intellectual property attorney, IP strategy analyst and legal advisor who counsels clients in patent strategy, portfolio management, patent prosecution, trademark protection, copyright filings, and trade secret matters. Additionally, he regularly advises Wall Street investors for Fortune 500 companies. He has over 25 years of legal experience and over 20 years specializing in intellectual property law.
Working as the U.S. Patent Counsel for IPSEN located in Paris, France, Alan was responsible for all of IPSEN’s IP in the U.S. (Pharm & Biopharma); Ireland (Manufacturing); and Spain (Drug Delivery Technology). Alan joined PCK to lead its U. S. Life Sciences division. He has experience serving as in-house counsel, managing outside counsel, and working in private practices, including:
- Executive-level management in pharmaceutical and biotech industry with a major focus on Small & Large Molecule, Protein & Peptide, and Biological IP development
- Leading IP strategy and development for R&D teams in chemistry, biology, manufacturing processes, instruments, and drug delivery systems
- Chief US IP Counsel for multinational biopharmaceutical company with approx. thirty (30) affiliates world-wide
- Strong experience in drug discovery and development, peptide engineering, protein engineering, medicinal chemistry, biotechnology, project management, and alliance management for all aspects of IP portfolio management
- Strategy in dispute resolution and litigation
- Managed trademark group for major Boston law firm, named outstanding trademark practice of the year
Alan was a former examiner in the biotechnology and biomedical unit for the United States Patent and Trademark Office. He specializes in the procurement and enforcement of intellectual property rights, including patents, trademarks, and copyrights. Other scientific areas of his practice include molecular diagnostics, oncology, medical devices, mechanical and materials sciences.
EDUCATION
Master of Laws in Intellectual Property (LL.M.), University of New Hampshire, 1997
Juris Doctor, University of Miami School of Law, 1990
Bachelor of Science, Chemistry, Boston College, 1987
MEMBER
International Trademark Association (INTA)
The Bar for the District of Columbia, June, 2017
Federal Bar for the District of Rhode Island, 2015
The Bar for the State of Rhode Island, 2014
Federal Bars for the Northern and Western Districts of New York, 1999
Federal Bar for the District of Massachusetts, 1998
United States Patent and Trademark Office, 1997
The Bar for the Commonwealth of Massachusetts, 1996
Federal Bar for the Southern District of Florida, 1994
The Bar for the State of Florida, 1990
SPEAKING ENGAGEMENTS
The Boston Children’s Hospital, Life Sciences New Ventures Program
Sino-French School of Oncology Research, Wuhan, China
The University of Rhode Island cGMP Innovations Lab, Board Member
Bryant University, Professional Series – Lecturer on IP for International Trade
Social Enterprise Greenhouse – Health & Wellness Initiative – Advisor, Presenter
US Life Sciences Trade Mission to Portugal 2015
Molecular Med Tri-Con 2013, San Francisco, CA
NOTABLE ACCOMPLISHMENTS
Former examiner for the US Patent and Trademark Office (USPTO) Biotechnology and Biomedical Research Group (subcontract)
Instrumental in the monetization of a neglected patent portfolio resulting in the creation of Rhythm Pharmaceuticals and raising $73 million in financing
Founding member of ERINE collaborative with Erasmus University (Rotterdam, NL)
Instrumental in securing one of the first grants ($1 million) awarded by the Massachusetts Life Sciences Center to one of IPSEN Pharmaceutical’s collaborators
Architect of the argument leading to European decision T 0578/06 which provided for the submission of post-published evidence to support inventive step
Drafter of Abaloparatide, Relamorelin, RM-493 and Taspoglutide as potential therapeutic agents for treating osteoporosis, GI functional disorders, obesity and type II diabetes, respectively
